AbbVie stock saw cautious retail sentiment amid reports of a potential $1 billion acquisition of Gilgamesh Pharmaceuticals. The deal would strengthen AbbVie’s mental health portfolio, boosting its psychiatric pipeline after Humira’s patent loss. Traders on Stocktwits remained ‘bearish’ as message volume stayed steady. The stock is up 5.5% YTD.